Regorafenib
Bayer
[]
#ascogi: integrate iia, a phase 3 study in refractory advanced gastroesophageal cancer led by the australasian gastro-intestinal trials group (#agitg). #gi23, #gasticcancer, #oesophagealcancer 
Driving innovation in cancer care for patients around the world.
Community guidelines: https://t.co/SCn8hWF4Mt